Pharmacy Benefit Manager (PBM) Market 研究

这 PBM market research is a crucial tool for comprehending the dynamics and trends of this industry. PBMs act as intermediaries in the healthcare system, assuming responsibility for managing prescription drug benefits for health plans, employers, and government programs.

他们与药品制造商协商确定药品价格、制定药品处方集并监督药房网络，以确保高效且经济地向患者提供药物。因此，随着医疗服务需求的不断增加，利益相关者和投资者对 PBM 市场研究产生了浓厚的兴趣。

什么是药房福利管理（PBM）市场研究？

PBM 市场研究包括一种获取、分析和理解与制药行业相关的数据的系统方法。该研究旨在提供有关当前市场状况的有用见解，例如规模、趋势、增长潜力、监管要求、竞争格局和消费者偏好。此外，它有助于确定维持行业发展的新机遇和障碍，使决策者能够做出明智的选择并制定有效的增长战略，以确保持续成功。

因此，组织可以深入了解推动 PBM 行业变革的因素，并获得有关市场未来的宝贵见解。这项研究对于健康计划、雇主、政府机构、制药商和其他行业利益相关者尤其有用，因为他们正在应对 PBM 市场复杂而竞争激烈的格局。

Pharmacy Benefit Manager PBM Market Research: How Leading Payers and Manufacturers Win

Pharmacy Benefit Manager PBM Market Research has become the decisive intelligence layer separating payers, manufacturers, and self-insured employers who optimize drug spend from those who absorb it. The pricing mechanics, rebate flows, and formulary control points inside PBMs are opaque by design. The firms that understand the mechanics gain leverage. The firms that do not, pay retail.

The market is consolidating around three vertically integrated players controlling roughly 80% of prescription claims volume in the United States: CVS Caremark, Express Scripts (Cigna), and OptumRx (UnitedHealth). Each pairs PBM operations with a health plan, a specialty pharmacy, and a mail-order channel. That structural shift changes what intelligence is worth gathering and how to gather it.

Why Pharmacy Benefit Manager PBM Market Research Now Drives Net Price Strategy

Gross-to-net erosion has reordered the priorities of pharmaceutical commercial teams. List price means little. Net price after rebates, administrative fees, manufacturer-funded copay assistance, 340B chargebacks, and DIR fees is what determines launch economics and lifecycle returns.

The introduction of the Inflation Reduction Act’s Medicare price negotiation, the FTC’s interim reports on PBM vertical integration, and state-level transparency statutes in Ohio, California, and New York have changed what data is accessible and what behavior is defensible. Manufacturers conducting payer value story development now stress-test formulary positioning against a regulatory backdrop that did not exist five years ago.

According to SIS International Research, the most effective payer engagement programs treat the PBM pharmacy and therapeutics committee, the health plan medical director, and the employer benefits consultant as three distinct buyers requiring three distinct evidence packages, rather than a single audience reached through one value dossier.

The Intelligence Gaps Where Leading Firms Compete

Conventional PBM research relies on syndicated claims data and published formulary lists. That tells you what already happened. It does not tell you why a drug was placed at Tier 3 with prior authorization, what rebate threshold would move it to Tier 2, or which competing manufacturer offered a portfolio deal that locked the slot.

The firms that win the formulary work the negotiation chain through primary research. Structured B2B expert interviews with former PBM trade relations directors, current pharmacy directors at regional health plans, and consultants at Mercer, Aon, and WTW yield the contracting logic that claims data cannot.

Three intelligence gaps consistently separate leading commercial teams from the rest:

Rebate aggregator economics. Ascent (Express Scripts), Zinc (CVS), and Emisar (Optum) sit between manufacturers and PBMs, capturing fee structures that rarely appear in published contracts. Understanding the spread between manufacturer rebate and plan sponsor pass-through is foundational to net pricing strategy.

Specialty pharmacy steerage. Accredo, CVS Specialty, and BriovaRx route limited-distribution drugs through channels owned by the same enterprise that adjudicates the claim. Market access strategy now depends on understanding which therapies face mandatory steerage and which retain choice at the patient level.

Employer carve-out behavior. Self-insured employers above 5,000 lives are increasingly carving out specialty pharmacy or partnering with transparent PBM challengers like Navitus, Capital Rx, and SmithRx. Tracking which industries and benefits consultants drive carve-out adoption signals where traditional rebate models lose ground.

What Leading PBM Market Research Programs Look Like

The strongest programs combine four methodologies in sequence rather than running them as one-off studies.

KOL mapping at the PBM and health plan level identifies the actual decision-makers on national and regional P&T committees, separating titular reviewers from voting influencers. Patient journey mapping for specialty therapies traces the prior authorization, step therapy, and accumulator adjustment touchpoints that determine real-world adherence. HTA submission evidence gets refined through payer advisory boards before ICER reviews, not after. Real-world evidence generation is sequenced to support the second-line indication that drives the lifecycle case.

In structured expert interviews SIS International has conducted with senior pharmacy and medical directors across North America and Latin America, the consistent pattern is that formulary decisions made in the first 90 days post-launch are rarely revisited for 18 to 24 months, making pre-launch payer research the highest-leverage commercial investment in the lifecycle.

Comparing the PBM Models Manufacturers Now Negotiate Against

Source: SIS International Research analysis of public PBM filings and primary expert interviews

The Geographic Expansion of PBM Models

The PBM construct is no longer purely American. Brazil, Mexico, and parts of the Gulf are introducing PBM-style intermediaries as private health insurance penetration grows and specialty drug spend accelerates. SIS International’s mixed-methodology research in Brazilian healthcare, combining quantitative provider sampling with qualitative payer interviews, indicates that Latin American PBM adoption is following a different sequence than the US, with employer-led procurement preceding insurer consolidation rather than the reverse.

For multinational manufacturers, that sequence matters. Market access strategy in São Paulo cannot be ported from Chicago. The negotiation counterparty, the rebate norms, and the formulary governance differ at the structural level.

The SIS Approach to PBM Intelligence

SIS International’s healthcare practice combines B2B expert interviews with former PBM executives, payer advisory boards with active P&T committee members, KOL mapping across specialty therapeutic areas, and competitive intelligence on rebate structures and specialty pharmacy steerage. The work is built for commercial leadership decisions: launch sequencing, indication prioritization, gross-to-net forecasting, and contracting strategy ahead of biosimilar entry.

The Pharmacy Benefit Manager PBM Market Research that drives commercial outcomes is not a deck of formulary screenshots. It is the negotiation logic, the rebate math, and the buyer-by-buyer evidence package that determines whether a launch hits its net price target.

Where the Opportunity Compounds

The manufacturers and self-insured employers investing in deeper Pharmacy Benefit Manager PBM Market Research now are buying optionality. Optionality to negotiate against vertically integrated incumbents. Optionality to evaluate transparent challenger PBMs without ideological bias. Optionality to redesign benefits before the next renewal cycle locks in another three years of rebate dependency. The intelligence gap is the commercial advantage.

关于 SIS 国际

SIS 国际 提供定量、定性和战略研究。我们提供决策所需的数据、工具、战略、报告和见解。我们还进行访谈、调查、焦点小组和其他市场研究方法和途径。 联系我们 为您的下一个市场研究项目提供帮助。